A clinical trial involving leuprolide, titled "Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer," was listed with a status update on October 15, 2026. The study, registered as NCT05617885, is a Phase 1 trial. Its current status is recorded as terminated. The available record does not state a reason for the termination. No results or outcome data are included in this status update. The trial evaluated darolutamide and abemaciclib in combination within a prostate cancer treatment context, with leuprolide noted as part of the regimen. Leuprolide itself remains an approved compound. This update reflects only a change in trial status as recorded in the registry entry. No efficacy or safety conclusions can be drawn from a termination status alone. Readers interested in further detail can consult the trial registry listing directly for any additional updates that may be posted in the future. For general background on leuprolide, including its approved uses and mechanism, readers can refer to the compound overview.
Leuprolide-Linked Trial Neo-DAB (NCT05617885) Marked Terminated
See the full leuprolide overview
Source: https://clinicaltrials.gov/study/NCT05617885